 |
2 Diseases |  |
4 Trials |
|
4 Trials |  |
151 News |  |
| «123» |
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Journal: Letter: elobixibatting for the long run. (Pubmed Central) - Apr 2, 2021
No abstract available
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P4 trial: TANK-27: Long-term Elobixibat for Chronic Constipation (clinicaltrials.gov) - Mar 4, 2021
P4, N=100, Not yet recruiting, Sponsor: Yokohama City University
- ||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Risankizumab got nothing on Elobixibat! (Twitter) - Feb 7, 2021
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment closed, Combination therapy: Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jan 7, 2021
P2a, N=100, Active, not recruiting, Sponsor: Yokohama City University
No abstract available Recruiting --> Active, not recruiting
- || elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Retrospective data, Review, Journal: Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review. (Pubmed Central) - Dec 17, 2020
(Curr Ther Res Clin Exp. 2020; 81:XXX-XXX).
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Journal: The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. (Pubmed Central) - Dec 16, 2020
Short term treatment with elobixibat increased the concentrations of total bile acids and deoxycholic acid and decreased the diversity of faecal microbiota. The biological effects of elobixibat are associated with its effects on secretory bile acids, rather than the structural changes of an altered faecal microbiota.
- || elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Review, Journal: Review article: Elobixibat: a novel treatment for chronic constipation. (Pubmed Central) - Dec 10, 2020
The biological effects of elobixibat are associated with its effects on secretory bile acids, rather than the structural changes of an altered faecal microbiota. This new class of compound appears to be safe and efficacious in the treatment of chronic constipation.
- || Review, Journal: The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs (Pubmed Central) - Nov 2, 2020
All of them are at different stages of clinical trials, which confirm the high efficacy and good tolerance of these inhibitors. Current trends in this field also include directed chemical synthesis of ASBT inhibitors, as well as their search among substances of plant origin.
- || elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, Journal: Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study. (Pubmed Central) - Oct 24, 2020
Elobixibat reduced the PAC-QOL scores for hemodialysis patients with chronic constipation and improved the patients' QOL. It may serve as a new option for treating constipation in hemodialysis patients.
- A3384 / Albireo, elobixibat (A3309) / Albireo, Ajinomoto, Ferring
[VIRTUAL] EFFICACY OF COMBINATION THERAPY WITH ELOBIXIBAT AND COLESTYRAMINE FOR NON-ALCOHOLIC STEATOHEPATITIS MODEL MICE TO PREVENT ARTERIOSCLEROSIS. () - Oct 11, 2020 - Abstract #AASLD2020AASLD_527;
Our findings clearly suggest ASBT inhibition in combination with BAS provide the promising therapeutic strategy for NASH with higher reduction of serum bile acid and tolerability compared to ASBT inhibitor monotherapy. In addition, it was found that a preventive effect on arteriosclerosis can be expected.
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
[VIRTUAL] DISCOVERY AND CHARACTERIZATION OF NOVEL BILE ACID TRANSPORTER INHIBITORS WITH POTENTIAL FOR TREATMENT OF LIVER DISEASES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_348;
We have identified novel systemically available BAT inhibitors with the potential to target both ASBT/NTCP to block intestinal return of BAs and shunt BAs away from the liver and systemic circulation into urine for excretion from the body. A strategy using these or similar compounds may have potential for treatment of liver diseases.
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion: A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH (clinicaltrials.gov) - Aug 16, 2020
P2, N=47, Completed, Sponsor: Albireo
A strategy using these or similar compounds may have potential for treatment of liver diseases. Active, not recruiting --> Completed
- || elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, Observational data, Journal: Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study. (Pubmed Central) - Aug 4, 2020
Elobixibat improved not only the frequency of bowel movements but also alleviated various symptoms of constipation, such as difficulty with evacuation and sensations of incomplete evacuation in elderly patients with chronic constipation. All adverse drug reactions were mild in severity with no safety concerns.
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion date, Trial primary completion date, Combination therapy: Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 23, 2020
P2a, N=100, Recruiting, Sponsor: Yokohama City University
All adverse drug reactions were mild in severity with no safety concerns. Trial completion date: Sep 2020 --> Jun 2021 | Trial primary completion date: Aug 2020 --> Apr 2021
- A3384 / Albireo, elobixibat (A3309) / Albireo, Ajinomoto, Ferring
[VIRTUAL] Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1455;
The phase 2 study of volixibat, an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), for NASH was conducted but resulted in early termination due to lack of efficacy and occurrence of adverse events. Our findings clearly suggest ASBT inhibition in combination with BAS provide the promising therapeutic strategy for NASH with higher reduction of serum bile acid and tolerability compared to ASBT inhibitor monotherapy.
- || Retrospective data, Review, Journal: Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. (Pubmed Central) - May 28, 2020
Prucalopride ranked first at 12 weeks, and many of the included trials recruited patients who previously did not respond to laxatives, suggesting that this drug is likely to be the most efficacious for patients with chronic idiopathic constipation. However, because treatment duration in most trials was 4-12 weeks, the long-term relative efficacy of these drugs is unknown.
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Retrospective data, Journal: The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study. (Pubmed Central) - May 16, 2020
There were no significant effect-related factors for gender, age, and use of laxatives. Short-period elobixibat is shown to be effective also for the elderly and male.
- ||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment open, Combination therapy: Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - May 14, 2020
P2a, N=100, Recruiting, Sponsor: Yokohama City University
Short-period elobixibat is shown to be effective also for the elderly and male. Not yet recruiting --> Recruiting
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
THE EFFICAY OF ELOBIXIBAT AS AN INHIBITOR OF ILEAL BILE ACID TRANSPORTER FOR CHRONIC CONSTIPATION -A MULTICENTER COHORT STUDY- () - May 4, 2020 - Abstract #DDW2020DDW_4765;
The rate of adverse events was 15.2% (diarrhea: 8.9%, abdominal pain: 6.3%, abdominal fullness: 2.5%, and nausea: 0.6%). [Conclusion] The efficacy and safeness of elobixibat were confirmed for patients including the elderly in a multicenter study
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Changes in the gut microbiota caused by ASBTi suppress intrahepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). (Board Number: P749) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_2260;
These results suggest that changes in the gut microbiota caused by ASBTi suppress intrahepatic steatosis and inflammation in NAFLD mice. Elobixibat can be expected to prevent fatty liver.
- ||| elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, P3 data, Retrospective data, Journal, HEOR: Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. (Pubmed Central) - Apr 14, 2020
Elobixibat can be expected to prevent fatty liver. Elobixibat is effective for symptomatically severe constipation, is well tolerated and improves QOL, irrespective of potentially confounding patient characteristics.
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment closed: A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH (clinicaltrials.gov) - Mar 31, 2020
P2, N=47, Active, not recruiting, Sponsor: Albireo
Elobixibat is effective for symptomatically severe constipation, is well tolerated and improves QOL, irrespective of potentially confounding patient characteristics. Recruiting --> Active, not recruiting
- A3384 / Albireo, elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice. (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1762;
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
THE EFFECT OF ELOBIXIBAT ON GUT MICROBIOTA AND THE CHANGE OF FECAL CONCENTRATION OF BILE ACID: A PROSPECTIVE, SINGLE-CENTER, NON-BLINDED, SINGLE-ARM, CLINICAL TRIAL. () - Jan 28, 2020 - Abstract #DDW2020DDW_2018;
Increased concentrations of BAs by administration of elobixibat decreased diversity of gut microbiota in the feces and changed some gut microbiota. This is the first study that artificially increased BAs in humans and examined changes on gut microbiota
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR, INCREASES FECAL BILE ACIDS IN PATIENTS WITH CHRONIC CONSTIPATION () - Jan 28, 2020 - Abstract #DDW2020DDW_1999;
Conclusions Despite no difference in total fecal BA concentrations between healthy and constipated subjects, CC patients showed reduction in fecal primary BA concentration compared to healthy subjects. Elobixibat improvement of constipation is associated with increased total BAs and, in particular, primary BAs.
- |||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P2a trial, Combination therapy: Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Jan 21, 2020
P2a, N=100, Not yet recruiting, Sponsor: Yokohama City University
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Journal: Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs. (Pubmed Central) - Nov 6, 2019
Elobixibat induces bowel movements faster than sennoside through a different mechanism. Elobixibat locally inhibits IBAT in the ileal lumen, leading to elevated fecal BAs in the colon and induced mild GMCs during defecation.
- elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Impact of Elobixibat on Chronic Constipation in Patients on Hemodialysis Assessed Using the Patient Assessment of Constipation-Quality of Life Questionnaire (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1781;
Conclusion Administration of elobixibat to hemodialysis patients with chronic constipation reduced the scores of PAC-QOL and improved the patients’ QOL. Elobixibat may therefore serve as a new option for the treatment of constipation in hemodialysis patients.
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, Journal: Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomised controlled trial. (Pubmed Central) - Oct 13, 2019
Elobixibat should be taken before breakfast. Once-daily administration of elobixibat was found to be safe and tolerated up to 20 mg in female and male patients with CC.
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P2 trial: A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH (clinicaltrials.gov) - Jul 4, 2019
P2, N=46, Recruiting, Sponsor: Albireo
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Journal: Elobixibat for the Treatment of Constipation. (Pubmed Central) - Jun 7, 2019
Further studies are required to confirm efficacy for relief of CC. Once approved, elobixibat will likely become a second-line choice for treatment of CC.
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, Journal: Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE tablet 5 mg) (Pubmed Central) - May 5, 2019
In addition, the safety/tolerability of elobixibat administered once daily for 52 weeks was considered to be acceptable. Therefore, elobixibat has a mechanism of action that differs from any of the existing therapeutic agents for constipation and is expected to become one of the new treatment options for chronic constipation.
- | elobixibat (A3309) / Albireo, Ajinomoto, Ferring
Clinical, P2 data, Journal: Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. (Pubmed Central) - Apr 26, 2019
Therefore, elobixibat has a mechanism of action that differs from any of the existing therapeutic agents for constipation and is expected to become one of the new treatment options for chronic constipation. Our study results suggest that 10 mg of elobixibat is a clinically optimal dose for Japanese patients with chronic constipation.
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment change, Trial withdrawal: Elobixibat Colonic Motor Function Study (clinicaltrials.gov) - Jun 11, 2015
P2, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Our study results suggest that 10 mg of elobixibat is a clinically optimal dose for Japanese patients with chronic constipation. N=36 --> 0 | Not yet recruiting --> Withdrawn
- ||||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 21, 2015
P3, N=411, Completed, Sponsor: Ferring Pharmaceuticals
N=36 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P2 trial: Elobixibat Colonic Motor Function Study (clinicaltrials.gov) - Mar 20, 2015
P2, N=36, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- ||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment closed, Enrollment change, Trial primary completion date: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Aug 29, 2014
P3, N=411, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=900 --> 411 | Trial primary completion date: Oct 2015 --> May 2015
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial primary completion date: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Active, not recruiting | N=900 --> 411 | Trial primary completion date: Oct 2015 --> May 2015 Trial primary completion date: Aug 2014 --> Apr 2014
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion date: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Aug 2014 --> Apr 2014 Trial completion date: Sep 2014 --> May 2014
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial termination: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Trial completion date: Sep 2014 --> May 2014 Suspended --> Terminated; Terminated due to a distribution issue with the trial medication
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment change: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - May 6, 2014
P3, N=374, Terminated, Sponsor: Ferring Pharmaceuticals
Suspended --> Terminated; Terminated due to a distribution issue with the trial medication N=840 --> 374
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial primary completion date: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
N=840 --> 374 Trial primary completion date: Jun 2014 --> Mar 2014
- Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial completion date: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jun 2014 --> Mar 2014 Trial completion date: Sep 2014 --> Apr 2014
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial termination: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Trial completion date: Sep 2014 --> Apr 2014 Suspended --> Terminated; Terminated due to a distribution issue with the trial medication
- | Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment change: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 27, 2014
P3, N=314, Terminated, Sponsor: Ferring Pharmaceuticals
Suspended --> Terminated; Terminated due to a distribution issue with the trial medication N=840 --> 314
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial suspension: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jan 28, 2014
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
N=840 --> 314 Recruiting --> Suspended
- || Goofice (elobixibat) / Eisai, Mochida, Ipsen
Trial suspension: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jan 28, 2014
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
Recruiting --> Suspended Recruiting --> Suspended
- |||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Enrollment open: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Sep 23, 2013
P3, N=900, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
Recruiting --> Suspended Not yet recruiting --> Enrolling by invitation
- |||||||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P3 trial: Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Jul 8, 2013
P3, N=900, Enrolling by invitation, Sponsor: Ferring Pharmaceuticals
- ||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P3 trial: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 14, 2013
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals